For human immunodeficiency virus type 1 (HIV-1) to infect a cell, the viral envelope protein (Env) must interact with CD4 and a coreceptor, thereby inducing conformational changes in Env that mediate fusion between the viral and cellular membranes (1, 8, 9, 11, 12, 15) . The efficiency of virus infection can be modulated by receptor density, by the inherent fusogenicity of the Env protein, and by cellular factors that enhance virus attachment to the cell surface (10, 13, 27) . Attachment of HIV-1 to the cell surface can occur independently of CD4, and attachment can result in more efficient infection (36) . Attachment can be due to interactions between Env and cell surface molecules. Alternatively, proteins that are incorporated into the viral membrane during budding can subsequently interact with their native ligands on the cell surface. For example, ICAM-1 incorporated into the viral membrane can bind to cell surface LFA-1, enhancing infection of both cell lines and lymphoid tissue by HIV-1 (6) .
A cell surface molecule that can enhance virus infection by binding to the viral Env protein is DC-SIGN (3, 17, 28) . DC-SIGN is a type II integral membrane protein that is expressed on dendritic cells (DCs) and on some types of tissue macrophages, including Hofbauer cells in human placenta (17, 33, 34) . In addition, DC-SIGN expression can be induced on monocyte-derived macrophages by interleukin 13 (IL-13) treatment (34) . DC-SIGN forms a homotetramer and contains a carbohydrate recognition domain that preferentially binds endogenous high-mannose oligosaccharides (14, 26) . While the physiological ligands for DC-SIGN include ICAM-2 and ICAM-3 (16, 18) , all HIV-1, HIV-2, and simian immunodeficiency virus (SIV) strains examined to date also bind DC-SIGN (17, 29) . Binding of virus to DC-SIGN can enhance HIV infection both in cis (22) and in trans (17) . Thus, virus bound to a DC-SIGN-positive cell can be transmitted to a cell that expresses CD4 and an appropriate coreceptor. It has been proposed that DC-SIGN may provide the molecular explanation for the efficiency with which DCs capture HIV and transmit it to T cells during the formation of an immunological synapse (7, 19, 32, 37) . In addition, it has been posited that HIV may encounter and adhere efficiently to mucosal DCs by DC-SIGN at the site of entry and then be ferried to secondary lymphoid organs where infection can proceed (17) . If this model is correct, then HIV interactions with DC-SIGN could represent a new molecular target for antiviral therapy, particularly in the context of microbicides. DC-SIGN also binds the Ebola virus glycoprotein, and cells expressing DC-SIGN are infected by Ebola virus more efficiently (G. Simmons et al., submitted for publication). Thus, other pathogens may interact with DC-SIGN in a manner that affects virus tropism or pathogenesis.
In this study, we have extended our characterization of a panel of monoclonal antibodies (MAbs) directed against the carbohydrate recognition domain of DC-SIGN (21) . Using a MAb directly conjugated to a fluorochrome, we found that monocyte derived DCs (MDDCs) from normal human donors express high levels of DC-SIGN, often in excess of 250,000 copies per cell. Differences in expression between individuals rarely exceeded three-to fourfold and were similar to differences in expression seen on DCs isolated at different times from the same individual. A subset of the MAbs efficiently blocked HIV interactions with DC-SIGN on two different cell lines. Binding and infection of virus pseudotypes bearing the Ebola virus glycoprotein was also inhibited. However, the MAbs reduced transmission of HIV from DCs to CD4/coreceptor-positive cell lines by a maximum of only 50%. A competitive inhibitor of DC-SIGN (mannan) reduced virus transmission from DCs by a similar amount. Thus, we conclude that while DC-SIGN contributes to the ability of DCs to capture and transmit HIV, other molecules are also likely to play a significant role.
MATERIALS AND METHODS
Cells and cell lines. To obtain MDDCs, we purified monocytes from peripheral blood mononuclear cells by discontinuous Percoll gradient centrifugation. The low-density fraction (monocyte enriched) was further depleted of lymphocytes by a 2-h plastic adhesion step at 37°C followed by extensive washing in prewarmed culture medium. This resulted in highly purified monocytes as determined by flow cytometry using anti-CD14 (90 to 95% positive) or anti-CD11c (95 to 98% positive) MAbs. To generate immature MDDC, purified monocytes were cultured in RPMI 1640 supplemented with granulocyte-macrophage colony-stimulating factor (50 ng/ml) and IL-4 (100 ng/ml) for 7 days. Each batch of immature MDDCs was analyzed by flow cytometry and had the following phenotype: HLA-DR high CD11c high CD14 Ϫ CD80 ϩ CD83 Ϫ (data not shown). Previously described stably DC-SIGN-or DC-SIGNR-transfected 293 cells were used for flow cytometry, ICAM-3 and virus binding, and for virus transmission experiments (29, 30) . THP cells expressing DC-SIGN were kindly provided by Dan Littman (New York University) and have been described previously (17) .
Antibodies. A phycoerythrin (PE)-conjugated goat anti-mouse Fab fragment (Caltag, Burlingame, Calif.) was used as a secondary antibody for standard fluorescence-activated cell sorter (FACS) assays. PE-conjugated DC11 was used for all quantitative FACS measurements (4). We used a previously characterized panel of MAbs specific for the lectin domain of DC-SIGN and/or DC-SIGNR (21) . These MAbs were obtained by immunizing mice with murine 3T3 cells expressing human DC-SIGN or DC-SIGNR, and MAbs were produced as previously described (21) . The name and isotypes of the antibodies are as follows: 506 (clone 120506, immunoglobulin G2a [IgG2a]), 507 (clone 120507, IgG2b), 516 (clone 120516, IgG2a), 518 (clone 120518, IgG2a), 526 (clone 120526 IgG2a), 531 (clone 120531, IgG1), 604 (clone 120604, IgG2b), and 612 (clone 120612, IgG2a). Alophycocyanin-conjugated HLA-DR, fluorescein isothiocyanate-conjugated CD14, fluorescein isothiocyanate-conjugated CD80, and tricolor-conjugated CD83 were all obtained from Caltag. Cy-chrome-conjugated CD11c was purchased from Pharmingen (San Diego, Calif.).
Generation of virus stocks. Stocks of replication-competent luciferase reporter viruses were generated as described previously (29, 30) . In brief, 293T cells were calcium phosphate-transfected with the proviral genomes, and the culture medium was replaced by fresh Dulbecco's modified Eagle medium (DMEM) 18 h after transfection. The culture supernatant was harvested 48 h after transfection, sterile filtered using 0.45-m-pore-size filters, divided into aliquots, and frozen at Ϫ80°C. The amount of p24/p27 viral antigen in the supernatants was quantified using commercially available antigen capture enzyme-linked immunosorbent assay (ELISA) kits. HIV pseudotypes bearing the Ebola Zaire strain glycoprotein (EboZ-GP) were generated in a similar manner. However, 293T cells were cotransfected with an Env-defective proviral HIV genome harboring the luciferase gene in place of nef and an expression vector encoding the glycoprotein of the EboZ-GP.
Cell culture. 293T cells were maintained in DMEM supplemented with 10% fetal calf serum. T-REX cells (Invitrogen) expressing DC-SIGN or DC-SIGNR upon induction with doxycycline (Sigma, St. Louis, Mo.) were maintained in DMEM supplemented with 10% fetal calf serum, 100 g of Zeocin (Invitrogen)/ ml, and 5 g of blasticidin (Invitrogen)/ml. Parental T-REX cells were cultivated in the same medium, but without Zeocin. CEMx174, C8166, and THP DC-SIGN as well as parental THP cells were cultured in RPMI 1640 medium containing 10% fetal calf serum and penicillin-streptomycin.
Flow cytometry and quantification. Stably DC-SIGN-or DC-SIGNR-transfected 293 cells, treated overnight with doxycycline, or MDDCs were stained in FACS buffer (phosphate-buffered saline supplemented with 3% fetal calf serum and 0.02% sodium azide) for 30 min on ice with MAbs at a final concentration of 10 g/ml. The samples were washed and incubated with PE-conjugated goat anti-mouse Fab fragments (Caltag) (1/100) for 30 min on ice and then washed and resuspended in FACS buffer containing 2% paraformaldehyde. The samples were analyzed with a FACScan (Becton Dickinson, San Jose, Calif.) cell analyzer using the CellQuest software for data evaluation. Dead cells were excluded on the basis of their forward-and side-scatter characteristics. For quantification we used the Quantum Simply Cellular microbead kit from Sigma according to the manufacturer's instructions and as previously described (24, 30) . Briefly, quantification was performed by converting the geometrical mean channel fluorescence (GMCF) into antibody-binding sites (ABS). The kit contains a mixture of five microbead populations of uniform size, coated with goat anti-mouse antibodies, that have differing abilities to bind mouse antibodies (i.e., ranging from 0 to ϳ250,000 molecules). PE-conjugated CD11 was added at saturating amounts to cells and separately to 100,000 beads. All samples including the beads were processed and analyzed identically. The binding capacities of the stained microbeads were then regressed against the corresponding GMCF of each bead population, and the GMCF of the antigen analyzed on the sample cells was converted to ABS per cell by comparison with the regression curve generated. The GMCF of the isotype control for each experiment was converted to ABS and subtracted from the ABS value obtained with the experimental sample.
ICAM-3 binding assays. We used the assay we have previously described (2) . Briefly, soluble Fc-ICAM-3 protein (R&D Systems, Minneapolis, Minn.) was iodinated by using Iodogen (Pierce). Specific activities of 500 to 2,000 Ci/mmol were obtained by using 5 g of protein with 500 Ci of Na 125 I for 20 min in 5-ml glass tubes precoated with 10 g of Iodogen by chloroform evaporation. Radiolabeled proteins were purified from free Na 125 I by separation through a 0.3-ml Dowex column prepared in a 1-ml syringe and preequilibrated in a mixture containing 50 mM HEPES (pH 7.4), 5 mM MgCl 2 , 1 mM CaCl 2 , 1% bovine serum albumin (BSA), and 150 mM NaCl. Protein fractions were eluted in the void volume of the column, and the fractions containing peaks of labeled protein were combined. Stably DC-SIGN-or DC-SIGNR-transfected cells were induced overnight with doxycycline, washed once with phosphate-buffered saline, and resuspended in binding buffer (50 mM HEPES [pH 7.4], 2 mM magnesium chloride, 2 mM calcium chloride,; 0.5% BSA). Cells (10 6 ) were incubated with 50,000 cpm of Fc-ICAM-3 for 60 min at room temperature. Cells were collected onto Brandel grade GF/B filters with wash buffer (same as binding buffer plus 150 mM sodium chloride and no BSA) using a cell harvester. Filters were counted using a Wallac Wizard 1470 automatic gamma counter. Percent binding was determined by dividing the counts from the filters by the input radioactivity after deduction of the background counts obtained on parental 293 T-REX cells.
Inhibition of DC-SIGN/DC-SIGNR engagement by HIV and SIV particles and EboZ-GP-pseudotyped HIV particles. DC-SIGN/DC-SIGNR-expressing cells were seeded in 96-well plates and preincubated with 20 g of the DC-SIGN/ DC-SIGNR-specific MAbs or mannan/ml for 30 min. Thereafter the cells were typically pulsed with 15 ng of p24-normalized or 5 ng of p27-normalized luciferase reporter virus stocks/well for 3 h at 37°C. Unbound virus was removed by washing the cells three times with DMEM culture medium, and virus binding was quantified by lysing the cells in 1% Triton X-100 and assessing the amount of bound viral antigen by antigen capture ELISA. To determine transmission, the virus-pulsed cells were cocultivated with CEMx174 target cells and the luciferase activity in the cultures was measured 3 days after the start of the cocultivation. Blocking of EboZ-GP-mediated binding to DC-SIGN/DC-SIGNR was determined in a cis infection assay. T-REX cells were seeded in 96-well plates, induced with doxycycline to express the respective lectins, and preincubated with the MAbs as described above. Subsequently the cells were challenged with 5 ng of EboZ-GP-bearing HIV luciferase pseudotypes/well, and luciferase activity in the cultures was quantified 3 days after infection.
RESULTS

Affinities of lectin domain-specific MAbs for DC-SIGN.
We previously described the generation of eight MAbs directed against the lectin domain of DC-SIGN (21). One is specific for DC-SIGNR, four are specific for DC-SIGN, and three recognize both DC-SIGN and DC-SIGNR ( Table 1 ). The DC-SIGN-specific MAbs also recognize rhesus macaque DC-SIGN by FACS and by immunofluorescent staining of frozen tissue sections (21) . To further characterize this panel of MAbs, we determined their respective affinities for DC-SIGN or, in the case of the DC-SIGNR-specific MAb 604, DC-SIGNR. Stably transfected 293 cells were stimulated overnight with doxycycline to induce DC-SIGN or DC-SIGNR expression (29, 30) , stained with different concentrations of each MAb, and pro-cessed for FACS analysis. We found that all MAbs exhibited similar affinities for DC-SIGN and/or DC-SIGNR (Table 1) , with approximately 1.5 g of each MAb/ml being needed to obtain 50% of the maximum staining intensity, and that there were no significant differences in maximum staining intensities between the MAbs (2, 23). MAbs that recognized both DC-SIGN and DC-SIGNR bound to both proteins with similar affinities (data not shown).
DC-SIGN quantification on monocyte-derived DCs reveals very high copy numbers of DC-SIGN.
The ability of DC-SIGN to bind and transmit HIV is related in part to DC-SIGN expression levels (29) . To determine if there are significant differences in DC-SIGN expression on MDDCs that could impact virus transmission efficiency, we isolated monocytes from seven different donors three to five times each. MDDCs were derived by GM-CSF and IL-4 treatment for 7 days, and the MDDCs were shown by FACS to have the expected phenotype of immature DCs, i.e., HLA-DR high CD11c high CD14 Ϫ CD80 ϩ CD83 Ϫ (data not shown). Maturation of MDDCs as judged by CD83 upregulation (data not shown) was achieved by exposure to 100ng of lipopolysaccharides (LPS)/ml. DC-SIGN expression levels were measured using quantitative FACS, which provides a reproducible means for converting mean channel fluorescence values into ABS through the use of synthetic beads that bind fixed numbers of antibody molecules (24) . To eliminate errors associated with the use of secondary antibodies, we used MAb DC11 directly conjugated to PE at saturating levels. However, similar results were also obtained with a MAb directed to the carbohydrate recognition domain of DC-SIGN (data not shown). While there was variation in DC-SIGN expression on MDDCs from the same donor over time as well as between donors (Fig. 1) , DC-SIGN was always expressed in excess of 100,000 copies per cell, and often at much higher levels. On cell lines, we have found that approximately 60,000 copies of DC-SIGN are needed for efficient virus transmission activity (29) . It is important to note that the quantitative FACS assay can accurately measure ABS values to approximately 250,000. Values in excess of this are derived from projecting the standard curve beyond the last standard and so should not be deemed as definitive. These experiments show that for the individuals examined, DC-SIGN is expressed at high levels on T-REX cells were induced to express DC-SIGN or DC-SIGNR and were preincubated with the indicated MAbs or mannan, a carbohydrate that blocks virus interactions with both DC-SIGN and DC-SIGNR (17) . The cells were subsequently pulsed with HIV-1 NL4-3 luciferase reporter virus, extensively washed, and either lysed with the amount of bound virus being quantified by p24 ELISA or cocultivated with target C8166 cells. The efficiency of virus transmission was then assessed by quantifying the luciferase activity in the cocultures 3 days later (Fig. 3A) .
We found that five out of the eight antibodies that were tested efficiently blocked virus binding and transmission (Fig.  3A) from DC-SIGN-expressing cells, inhibiting both functions by at least 70% compared to the mock control. Preincubation with mannan inhibited binding and transmission to a comparable degree. In contrast, a control mouse immunoglobulin as well as the DC-SIGNR-specific MAb 604 and the DC-SIGNspecific MAb 507 had no significant effect on HIV binding to DC-SIGN. The MAb 518 exhibited detectable blocking activity in this cellular context, inhibiting virus binding to about 50% and transmission to about 30% relative to the mock control. HIV interactions with DC-SIGNR were efficiently blocked by the DC-SIGNR-specific MAb 604 and the dual-specific MAb 612, both of which reduced binding and transmission by at least 85% compared to the mock and mouse IgG (mIgG) controls (Fig. 3B) . MAb 526 also reduced virus binding and transmission via DC-SIGNR, though less efficiently than was observed with MAbs 604 and 612. (Fig. 3C) . Seven out of eight MAbs reduced binding and transmission to background levels. Even MAb 507, which did not significantly inhibit DC-SIGN engagement on T-REX cells, reduced binding and transmission from THP cells to about 10%, whereas the MAbs 516 and 526 diminished both functions to about 3% compared to the mock control.
Antibody inhibition of SIV transmission by rhesus macaque DC-SIGN. The experimental inoculation of macaques with SIV is one of the most commonly used animal models for the HIV infection in humans. DCs in the rectal and vaginal mucosa of rhesus macaques express DC-SIGN (21) . The importance of DC-SIGN for virus transmission in vivo could thus be evaluated by investigating whether interference with DC-SIGN function inhibits viral spread in macaques after a vaginal or rectal challenge. We have previously shown that MAb 507 inhibits binding and transmission of SIV to and from rhesus macaque DC-SIGN (21) . Here, we tested the entire panel of MAbs for the ability to inhibit SIV transmission by rhesus macaque DC-SIGN (Fig. 4) . T-REX cells expressing rhesus DC-SIGN were preincubated with the indicated MAbs, challenged with SIV luciferase reporter virus bearing the M-tropic 239 MER Env protein, vigorously washed, and cocultivated with target cells. Virus transmission was assessed by quantifying the luciferase activity in the cocultures 3 days later. We found that only MAbs 507 and 526 efficiently inhibited virus transmission by rhesus macaque DC-SIGN (Fig. 4) .
Virus transfer by MDDCs does not solely depend on DC-SIGN. Dendritic cells express DC-SIGN, CD4, and perhaps other molecules that could serve as attachment factors for HIV. To examine the role of DC-SIGN in this process, MDDCs were matured by exposure to LPS and preincubated with the indicated MAbs or mannan. The cells were pulsed with the virus strain NL4-3. After binding for 2 h, the cells were washed extensively and cocultured with CEMssR5 target cells. Luciferase activity in the cultures was quantified 3 days later. Mannan reduced transmission of NL4-3 by only 56% compared to results with the mIgG controls (Fig. 5) . MAb 506 blocked transmission with the greatest efficiency, reducing infection in trans by 69% for HIV-1 NL4-3 relative to the mIgG controls. Direct addition of virus to DCs did not result in efficient infection (data not shown), indicating that the luciferase activity in the cocultures was due to infection of the target cells. When immature MDDCs were used, inhibition of virus transmission by the MAbs and by mannan was somewhat less efficient and more variable (data not shown). Thus, even though mannan treatment as well as some DC-SIGN-specific MAbs efficiently blocked DC-SIGN-mediated virus binding and transmission to and from THP and 293 cells, inhibition of virus transmission from either mature or immature MDDCs was inefficient. These results indicate that other molecules play important roles in virus transmission from MDDCs or that the MAbs and mannan fail to inhibit virus interactions with DC-SIGN in the context of dendritic cells.
Antibody blocking of EboZ-GP engagement of DC-SIGN and DC-SIGNR. We recently found that DC-SIGN/DC-SIGNR bind to the glycoprotein (GP) of Ebola virus and strongly enhance infection of target cells in cis (Simmons et al., submitted). The expression of these lectins on critical targets of Ebola infection suggests that DC-SIGN/DC-SIGNR might play an important role in Ebola virus dissemination in and between hosts. We investigated whether the MAbs inhibited EboZ-GP mediated engagement of these lectins. T-REX cells expressing the indicated lectins were preincubated with the panel of MAbs or mannan and challenged with Env-defective HIV luciferase reporter viruses bearing the EboZ-GP, and luciferase activity was determined 3 days after infection (Fig.   FIG. 4 . Inhibition of SIV transmission mediated by rhesus macaque DC-SIGN. The ability of the MAbs to inhibit transmission of a SIVmac239 MER Env reporter virus was assessed as described in the legend to Figure 3 ; however, T-REX cells expressing rhesus macaque DC-SIGN were used and were preincubated with 30 g of the MAbs/ ml. The infection efficiency is presented relative to mock-treated cells. The average Ϯ standard error of the mean for three independent experiments, each performed in quadruplicate, is shown. In a representative experiment transmission from rhesus macaque DC-SIGN cells in the absence of inhibitors resulted in a luciferase activity of 1,920 cps whereas pretreatment with mannan reduced luciferase activity to 531 counts. 
DISCUSSION
Intraepithelial and mucosal dendritic cells are among the first cells encountered by HIV during sexual transmission. Studies with rhesus macaques show that DCs in the vaginal mucosa can be infected by virus, though other infected cell types can be found as well (20, 35, 39) . Virus has been found in draining lymph nodes within 18 h of intravaginal SIV exposure, indicating that virus is disseminated rapidly within the host (20) . These and other studies are consistent with a model in which DCs interact with virus, migrate to draining lymph nodes, and transmit virus to CD4 ϩ T lymphocytes (20, 25, 35) . In vitro studies support the idea that DCs play an important role in the transmission and dissemination of HIV in vivo. DCs are particularly effective at capturing HIV and transferring it to adjacent CD4 ϩ T cells, even when the DCs are not infected themselves (7, 19, 32, 37) . Furthermore, virus captured by DC-SIGN can remain infectious for a prolonged period of time (17) , again consistent with a model in which DCs ferry virus from a distal, mucosal site to a more proximally located secondary lymphoid organ.
The mechanisms by which DCs capture and transmit HIV are incompletely understood. However, the discovery that the C-type lectin DC-SIGN is expressed on DCs and binds to HIV-1 gp120 with high affinity represents an important first step in understanding this process (17) . DC-SIGN binds to endogenous high-mannose oligosaccharides that are present on the HIV-1 Env protein as well as on ICAM-2 and ICAM-3, the normal cellular ligands for DC-SIGN (14, 16, 18, 26) . The tetrameric nature of DC-SIGN may also play an important role in binding and mediating specificity, since several binding events between a ligand and DC-SIGN may be needed to confer a high-avidity interaction (26) . When expressed on cell lines, DC-SIGN functions as a universal attachment factor for primate lentiviruses, binding to all HIV-1, HIV-2, and SIV strains studied to date (17, 29) . Once bound to a DC-SIGNpositive cell, virus can be transmitted to cocultured cells that express CD4 and an appropriate coreceptor, recapitulating at least in part the ability of DCs to propagate virus infection in vitro.
DC-SIGN is expressed on MDDCs, a proportion of human alveolar macrophages, and decidual macrophages and Hofbauer cells in human placenta (17, 33, 34) . In addition, its expression can be induced on monocyte-derived macrophages by IL-13 treatment (34) . The in vivo distribution of DC-SIGN in intestinal and genital mucosae has also been examined (17, 21, 34) . In Peyer's patches, DC-SIGN-positive cells are found in the interfollicular regions and on clusters of cells in the subepithelial dome regions. Numerous DC-SIGN-positive cells are found throughout the entire thickness of the rectal mucosa, while in the vaginal epithelium DC-SIGN is found on subepithelial DCs in the lamina propria (21) . Thus, DC-SIGN is expressed on DCs at the major sites of HIV transmission, and it binds virus efficiently in vitro and mediates its transmission to other cells. A related molecule, termed DC-SIGNR or L-SIGN, functions in a similar manner but has a different distribution, being found on endothelial cells in the placenta, intestine, liver, and lymph nodes (5, 31) .
While DC-SIGN can clearly bind and transmit virus in vitro, to what degree is it responsible for the ability of DCs to potentiate infection of T-cells? Since DC-SIGN function is related to its surface expression, with approximately 60,000 copies of DC-SIGN being needed for efficient transmission of virus from DC-SIGN-positive 293 cells (29), we measured DC-SIGN expression on MDDCs using quantitative FACS (24) . If expression levels of DC-SIGN on DCs varied markedly between individuals, it could be determined whether differences in DC-SIGN expression levels correlate with differences in virus transmission efficiencies. However, at least with the small group of normal human donors we examined here, DC-SIGN was invariably expressed at high levels, with a minimum of 100,000 copies of DC-SIGN per MDDC. Variability in expression levels rarely exceeded a factor of 3 to 4, and there was as much variability in DC-SIGN expression levels between individuals as there was between cells isolated at different times from the same individual. The uniformly high levels of DC-SIGN expression on the MDDCs derived from our donor pool precluded us from drawing conclusions about DC-SIGN expression levels and virus transmission activity on this cell type.
As an alternative approach to assessing the role of DC-SIGN in binding of virus to DCs, infection of DCs, and transmission from DCs to adjoining receptor-positive cells, we screened MAbs for their ability to block virus interactions with DC-SIGN. The first panel of MAbs to DC-SIGN that we produced were generated against a bacterial fusion protein, with MAbs binding to epitopes in the repeat region predominating (4). None of these MAbs inhibited virus interactions with DC-SIGN, even though the repeat region itself is important for DC-SIGN interactions with HIV (29, 30) . However, the MAbs generated against murine cells expressing human DC-SIGN or DC-SIGNR bind determinants in the carbohydrate recognition domain and so are more likely to interfere with its function as a lectin. Indeed, some of the MAbs efficiently blocked interactions between HIV and DC-SIGN when it was expressed on either 293 or THP cells. Inhibition of virus binding to DC-SIGN-positive THP cells was particularly efficient. The MAbs also prevented binding of the heavily glycosylated EboZ-GP to DC-SIGN. Interestingly, none of the MAbs efficiently blocked binding of soluble ICAM-3 to DC-SIGN, suggesting that ICAM-3 and Env interact differently with DC-SIGN. Whether this is due to differences in affinity or more substantial differences in binding interactions remains to be determined.
Despite their ability to efficiently block virus interactions with DC-SIGN on cell lines, none of the MAbs efficiently blocked transmission of virus from MDDCs to cocultured Tcell lines. At best, approximately 50% inhibition was obtained when mature MDDCs were used. Inhibition of virus transmission from immature MDDCs by the MAbs was somewhat less efficient and more variable. We also used mannan, a carbohydrate that competitively inhibits ligand binding to DC-SIGN, and found that it too reduced virus transmission activity of MDDCs by approximately 50%. We consider the most likely interpretation of these results to be that DC-SIGN, expressed at high levels on MDDCs, does indeed play an important role in HIV binding and transmission, but that other cell surface molecules that have yet to be identified are also likely to participate in these interactions. Thus, the failure of mannan to completely block virus transfer from MDDCs suggests that one or more nonlectins, or lectins with different carbohydrate specificities, account for a significant portion of the ability of MDDCs to transmit HIV.
That molecules other than DC-SIGN can mediate virus transmission from MDDCs was recently shown by KewalRamani and colleagues, who showed that rhesus macaque MDDCs efficiently transmit SIV to T-cell lines (38) . Interestingly, the MDDCs expressed only low levels of DC-SIGN-probably below the levels needed to support virus transmission. Indeed, MAbs to rhesus DC-SIGN had no effect on the ability of rhesus MDDCs to transmit virus. Thus, molecules other than DC-SIGN must account for the ability of rhesus MDDCs to transmit virus to T cells. This should not, however, be taken to mean that rhesus DC-SIGN is not relevant for virus transmission in vivo. While DC-SIGN is not expressed on macaque MDDCs under the differentiation conditions examined thus far, tissue staining has shown that DC-SIGN is expressed in rhesus vaginal and rectal mucosae in a pattern similar to that seen in humans (21) . It must be admitted that our understanding of the factors that control DC-SIGN expression in vitro, and its pattern of expression on specific types of DCs in vivo, is far from complete.
Regardless of the role that DC-SIGN plays in HIV transmission in vitro and in vivo, its ability to efficiently bind virus and either boost infection in cis or mediate efficient infection in trans requires a reassessment of the role virus attachment plays in virus tropism and pathogenesis in general, and not just for HIV. Mucosal DCs are likely to express an array of proteins that enable them to recognize common structural motifs (like high-mannose carbohydrate chains) present on a wide variety of endogenous molecules and pathogens. It will be interesting to determine if pathogens other than HIV take advantage of the adhesive and migratory properties of DCs to enhance their infectivity and dissemination. As for HIV and DC-SIGN, the MAbs used here represent tools that may be used in attempts to determine the relevance of this interaction for virus infection and transmission in the rhesus macaque model.
